The aim of the first study was to describe prevalence and predictors of HIV virus associated fatty liver disease that in HIV-infected HAART- experienced patients are unknown.The aim of the second study was to ascertain a) the determinants of steatosis and insulin resistance in virus-associated fatty liver disease and b) the role of HIV, HCV and HIV/HCV as modulators of the relationship between MS and IR.
Antiretroviral drugs induced metabolic diseases in HIV infected patients / Guaraldi, Giovanni; A., Leonardo; S., Ballestri; Zona, Stefano; C., Stenterelli; Orlando, Gabriella; Carli, Federica; Carulli, Lucia; A., Roverato. - STAMPA. - 1:(2009), pp. 37-37. (Intervento presentato al convegno NAFLD/NASH and Related Metabolic Disease EASL Conference tenutosi a Bologna nel 24-26 Sep 2009).
Antiretroviral drugs induced metabolic diseases in HIV infected patients.
GUARALDI, Giovanni;ZONA, Stefano;ORLANDO, Gabriella;CARLI, FEDERICA;CARULLI, Lucia;
2009
Abstract
The aim of the first study was to describe prevalence and predictors of HIV virus associated fatty liver disease that in HIV-infected HAART- experienced patients are unknown.The aim of the second study was to ascertain a) the determinants of steatosis and insulin resistance in virus-associated fatty liver disease and b) the role of HIV, HCV and HIV/HCV as modulators of the relationship between MS and IR.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
